Abstract
Liver steatosis, or fatty liver, is characterized by the excess accumulation of triglycerides and fatty acids within hepatocytes. This accumulation is marked by an imbalance between the import/synthesis and export/degradation of fat in the liver. Liver steatosis is typically a benign condition, but is associated with severe complications following major liver surgery, as well as the progression of the liver to fibrosis, cirrhosis, and hepatocellular carcinoma. The hallmark of treatment has traditionally been the use of behavioral modification leading to long-term phenotypic reversal. However, the rapid reversal of liver steatosis is essential, especially prior to surgeries including hepatic resection or transplantation. The liver is a primary lipogenic tissue, making the enzyme fatty acid synthase (FAS, EC 2.3.1.85) a logical target for the treatment of steatosis. For steatosis of alcoholic or nonalcoholic etiology, fat accumulation is linked to the de novo synthesis of fatty acids through FAS. Recent reports have shown success using FAS inhibitors to reduce the amount of liver steatosis, and to reduce ischemia/reperfusion injury in those livers. Thus, FAS emerges as a key target for the reversal of hepatic steatosis, both for the preconditioning of livers prior to surgery.
Keywords: Fatty acid synthase liver, steatosis, transplantation, fatty liver disease, cerulenin, EGCG
Current Enzyme Inhibition
Title: Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis
Volume: 4 Issue: 3
Author(s): Zachary P. Evans, Justin D. Ellett and Kenneth D. Chavin
Affiliation:
Keywords: Fatty acid synthase liver, steatosis, transplantation, fatty liver disease, cerulenin, EGCG
Abstract: Liver steatosis, or fatty liver, is characterized by the excess accumulation of triglycerides and fatty acids within hepatocytes. This accumulation is marked by an imbalance between the import/synthesis and export/degradation of fat in the liver. Liver steatosis is typically a benign condition, but is associated with severe complications following major liver surgery, as well as the progression of the liver to fibrosis, cirrhosis, and hepatocellular carcinoma. The hallmark of treatment has traditionally been the use of behavioral modification leading to long-term phenotypic reversal. However, the rapid reversal of liver steatosis is essential, especially prior to surgeries including hepatic resection or transplantation. The liver is a primary lipogenic tissue, making the enzyme fatty acid synthase (FAS, EC 2.3.1.85) a logical target for the treatment of steatosis. For steatosis of alcoholic or nonalcoholic etiology, fat accumulation is linked to the de novo synthesis of fatty acids through FAS. Recent reports have shown success using FAS inhibitors to reduce the amount of liver steatosis, and to reduce ischemia/reperfusion injury in those livers. Thus, FAS emerges as a key target for the reversal of hepatic steatosis, both for the preconditioning of livers prior to surgery.
Export Options
About this article
Cite this article as:
Evans P. Zachary, Ellett D. Justin and Chavin D. Kenneth, Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis, Current Enzyme Inhibition 2008; 4 (3) . https://dx.doi.org/10.2174/157340808785909376
DOI https://dx.doi.org/10.2174/157340808785909376 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adjunctive Therapy for Percutaneous Revascularization in Acute Myocardial Infarction
Current Pharmaceutical Design The Use of Biomarkers for Assessing HAART-Associated Renal Toxicity in HIV-Infected Patients
Current HIV Research Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Autologous Fat Transfer and Cell-Based Strategies for Soft Tissue Reconstruction
Current Tissue Engineering (Discontinued) Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research Advancement of Targeted Ultrasound Contrast Agents and their Applications in Molecular Imaging and Targeted Therapy
Current Pharmaceutical Design Does Erythropoietin Always Win?
Current Medicinal Chemistry Use of Naturally Occurring Peptides for Neuropathic Spinal Cord Injury Pain
Current Protein & Peptide Science Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy Modulation of Mitochondrial Permeability Transition in Ischemia-Reperfusion Injury of the Heart. Advantages and Limitations
Current Medicinal Chemistry Increased Neutrophil-to-lymphocyte Ratios are Associated with Greater Risk of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke
Current Neurovascular Research Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication
Current Hypertension Reviews Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock
Current Genomics Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Interactions between Phytochemicals from Traditional Chinese Medicines and Human Cytochrome P450 Enzymes
Current Drug Metabolism Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology